Seeking Alpha

Soligenix (SNGX.OB) completes a Phase 1 study of its pediatric Crohn's disease treatment SGX203...

Soligenix (SNGX.OB) completes a Phase 1 study of its pediatric Crohn's disease treatment SGX203 which has Fast Track and Orphan Drug designation from the FDA. The study helped to "characterize the pharmacokinetic and pharmacodynamic" profile of the formula. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs